Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GUCY1B2 | O75343 | 9/20 | 0.40 |
| ▸ | GUCY1A2 | P33402 | 9/20 | 0.40 |
| ▸ | GUCY1A1 | Q02108 | 9/20 | 0.40 |
| ▸ | GUCY1B1 | Q02153 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7977505 | 0.83 | TDP1 (0.49) | LMNANPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7978626 | 0.79 | KMT2A (0.54) | MAPTSMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL7964747 | 0.76 | LMNA (0.65) | LMNANPC1RAB9AMAPTNPSR1 | |
| SCHEMBL7964745 | 0.74 | MAPT (0.52) | LMNANPC1RAB9AMAPTNPSR1 | |
| SCHEMBL1684439 | 0.73 | ALDH1A1 (0.55) | LMNANPC1RAB9AMAPTNPSR1 | |
| SCHEMBL1684435 | 0.73 | ALDH1A1 (0.55) | LMNANPC1RAB9AMAPTNPSR1 | |
| SCHEMBL7976791 | 0.72 | LMNA (0.53) | LMNANPC1RAB9AMAPTNPSR1 | |
| SCHEMBL30954413 | 0.71 | NPC1 (0.52) | LMNANPC1RAB9AMAPTNPSR1 | |
| SCHEMBL12295648 | 0.70 | KDM4E (0.60) | LMNASMN1; SMN2HTTGUCY1B2GUCY1A2 | |
| SCHEMBL7981635 | 0.70 | MAPT (0.43) | LMNANPC1RAB9AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | LMNA 1714/4885NPC1 2452/4885RAB9A 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.